

Author: Gratz S Kemke B Kaiser W Heinis J Behr TM Höffken H
Publisher: Field House Publishing
ISSN: 0300-0605
Source: The Journal of International Medical Research, Vol.38, Iss.2, 2010-03, pp. : 633-644
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The ability of integrated 18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET/CT) to distinguish between benign and malignant incidental non-secreting adrenal masses was evaluated in cancer patients. Results were compared with those of CT and shift magnetic resonance imaging (MRI). A total of 1832 cancer patients who had undergone FDG PET/CT scans were retrospectively evaluated. Visual interpretation, tumour maximum standardized uptake value (SUVmax), liver SUVmax and tumour/liver SUVmax ratios were correlated with the findings of CT, shift MRI and final diagnosis (based on biopsy or clinical/radiological follow-up). A total of 109 adrenal masses were found: 49 were malignant and 60 were benign on final diagnosis. A tumour/liver SUVmax ratio threshold of 1.0 was more accurate in differentiating the tumour type than tumour SUVmax or visual interpretation alone. Diagnostic accuracy of CT and shift MRI (92 – 97%) was similar to that for FDG PET/CT (94 – 97%). In conclusion, FDG PET/CT accurately characterizes adrenal tumours, with excellent sensitivity and specificity. Use of 1.0 as the threshold for the tumour/liver SUVmax ratio seems to be promising for distinguishing benign from malignant adrenal masses in cancer patients.
Related content


By Ibrahim Sherrif F. Ahronowitz Iris McCalmont Timothy H. Hernandez Pampaloni Miguel Ryan Julie L. Yu Siegrid S.
Dermatologic Surgery, Vol. 39, Iss. 9, 2013-09 ,pp. :


By Zincirkeser S Şahin E Halac M Sager S
The Journal of International Medical Research, Vol. 35, Iss. 2, 2007-03 ,pp. :




By Vollenweider F.X. Leenders K.L. Scharfetter C. Antonini A. Maguire P. Missimer J. Angst J.
European Neuropsychopharmacology, Vol. 7, Iss. 1, 1997-02 ,pp. :


Labeling Strategies with F-18 for Positron Emission Tomography Imaging
Medicinal Chemistry, Vol. 7, Iss. 5, 2011-09 ,pp. :